CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting by Norell, Håkan, Zhang, Yi, McCracken, James, Martins da Palma, Telma, Lesher, Aaron, Liu, Yueying, Roszkowski, Jeffrey J, Temple, Anquanette, Callender, Glenda G, Clay, Timothy, Orentas, Rimas, Guevara-Patiño, José, Nishimura, Michael I

Get full text